Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Actinium-225 (225Ac, Ac-225) is an isotope of actinium. It undergoes alpha decay to francium-221 with a half-life near 10 days, and is an intermediate decay product in the neptunium series (the decay chain starting at 237Np). Except for minuscule quantities arising from this decay chain in nature, 225Ac is entirely synthetic. The decay properties of actinium-225 (emitting four alpha particles within about an hour) are favorable for usage in targeted alpha therapy (TAT); clinical trials have demonstrated the applicability of radiopharmaceuticals containing 225Ac to treat various types of cancer. However, the scarcity of this isotope resulting from its necessary synthesis in cyclotrons limits its potential applications. Another such isotope, bismuth-213, is produced necessarily (given its short half-life) from the decay of actinium-225 in a generator and immediate use; it gives only the last of the four alpha particles, requiring a larger amount of actinium, but may be preferred if available.
== History == This method was developed by Solomon Berson and Rosalyn Sussman Yalow at the Veterans Administration Hospital in the Bronx, New York. This revolutionary development earned Dr. Yalow the Nobel Prize for Medicine in 1977, the second woman ever to win it. In her acceptance speech, Dr. Yalow said, "The world cannot afford the loss of the talents of half its people if we are to solve the many problems which beset us." Yalow shared the Nobel Prize with Roger Guillemin, and Andrew Schally who earned the prize based on their research into "the peptide hormone production of the brain".
=== Architecture === Between 1888 and 1892, Raymond traveled to ancient cities of Konya, Iznik, Bursa, Yenişehir and made drawings of Islamic architecture. From 1894, Raymond drew the blueprints for the Bursa Institute of Sericulture, an Ankara agency building – probably that of Régie de Tabac, and an Adapazarı agency building of Régie de Tabac. In 1908, he published L’Art de la Construction en Turquie (The Art of Construction in Turkey, in French), dealing with the construction market, material and labor conditions, and technical and legal arrangements in the Ottoman Empire at the beginning of the 20th century. He partnered with his brother César who ran a bookshop, Librairie Raymond, where his written works were sold.
Sources: en.wikipedia.org
== Further reading == Walker, John (November 21, 2007). "RPS Exclusive: Gabe Newell Interview". Rock, Paper, Shotgun. Bramwell, Tom (August 29, 2007). "Valve's Gabe Newell". Eurogamer. Gamer Network. Keighley, Geoff (November 12, 2004). "The Final Hours of Half-Life 2". GameSpot. CBS Interactive. Psycho_byte (June 26, 2003). "An interview with Gabe Newell". HL2Central. Game Central Network. Archived from the original on August 11, 2018. Retrieved February 9, 2016. Peterson, Andrea (January 3, 2014). "Gabe Newell on what makes Valve tick". The Washington Post.
Is it morally right to tamper with nature? Is one playing God when creating new life? What happens if a synthetic organism accidentally escapes? What if an individual misuses synthetic biology and creates a harmful entity (e.g., a biological weapon)? Who will have control of and access to the products of synthetic biology? Who will gain from these innovations? Investors? Medical patients? Industrial farmers? Does the patent system allow patents on living organisms? What about parts of organisms, like HIV resistance genes in humans? What if a new creation is deserving of moral or legal status? The ethical aspects of synthetic biology has three main features: biosafety, biosecurity, and the creation of new life forms. Other ethical issues mentioned include the regulation of new creations, patent management of new creations, benefit distribution, and research integrity. Ethical issues have surfaced for recombinant DNA and genetically modified organism (GMO) technologies and extensive regulations of genetic engineering and pathogen research were in place in many jurisdictions. Amy Gutmann, former head of the Presidential Bioethics Commission, argued that we should avoid the temptation to over-regulate synthetic biology in general, and genetic engineering in particular. According to Gutmann, "Regulatory parsimony is especially important in emerging technologies...where the temptation to stifle innovation on the basis of uncertainty and fear of the unknown is particularly great.
Dautch also teaches Jewish Culture and Holocaust Studies at the University of Roehampton and lectures at the London School of Jewish Studies and JW3. Lionel Davidson (Hull 1922–2009) thriller novelist, Golden Dagger winner, famous for "The night of Wenceslas", "Chelsea murders", "Kolinsky Heights". Lived briefly in Jaffa, Israel at the invitation of the government. Isaac Deutscher (Polish: Izaak Deutscher; 3 April 1907 – 19 August 1967); Polish Jewish Marxist author, journalist and political activist who moved to the United Kingdom before the outbreak of World War II; best known as a biographer of Leon Trotsky and as a commentator on Marxist dialectic and Soviet affairs. His three-volume biography of Trotsky was highly influential among the British New Left in the 1960s and 1970s. Michael Dickson (educator) (born 11 October 1977) dual citizen British-Israeli; author of ISRESILIENCE: What Israelis Can Teach the World; journalist for The Jerusalem Post, Times of Israel, Jewish Chronicle; executive director of StandWithUs Israel in Jerusalem; senior Fellow at Center for International Communication (CIC) of Bar Ilan University; Honorary member of Alpha Epsilon Pi; winner of the Bonei Zion Prize. Jenny Diski (8 July 1947 – 28 April 2016) was a countercultural protagonist, author and contributor to the UK Underground press, colleague of R.D. Laing, notable for starting the Freightliners free school.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.